Extracellular Volume Fraction Calculated Using Contrast-Enhanced Computed Tomography as a Biomarker of Oxaliplatin-Induced Sinusoidal Obstruction Syndrome: A Preliminary Histopathological Analysis
Table 2
Univariate analysis of the impact of the clinical valuables on sinusoidal obstruction syndrome.
Parameter
Grade 0
Grade 1 + 2
value
(n = 17)
(n = 9)
Patient characteristics
Age (years)
59.9 ± 10.8
66.1 ± 11.5
0.224
Sex (male/female)
9/8
8/1
0.067
Body mass index (kg/m2)
24.1 ± 6.0
21.6 ± 2.8
0.346
Chemotherapy
Purpose (NAC/unresectable, conversion)
11/6
5/4
0.648
Cycle of OX-based chemotherapy
10.3 ± 6.8
8.1 ± 5.7
0.471
Use of bevacizumab (yes/no)
10/7
3/6
0.216
Preoperative biologic data
AST (U/L)
23.4 ± 6.1
32.2 ± 13.3
0.100
Hematocrit (%)
38.7 ± 5.1
38.1 ± 5.7
0.628
Type IV collagen (ng/mL)
6.32 ± 1.78
8.26 ± 4.28
0.477
ICG R15 (%)
12.0 ± 11.3
12.3 ± 4.6
0.162
APRI
0.33 ± 0.12
0.53 ± 0.31
0.100
FIB-4 index
1.67 ± 0.84
2.28 ± 0.85
0.090
Histopathological finding
Fibrotic grading (Grade 0/1 or 2)
7/10
5/4
0.484
Imaging parameter
ECV fraction (%)
26.3 ± 3.4
30.6 ± 7.0
0.025
Increasing rate of SV (%)
114.2 ± 24.3
140.0 ± 56.8
0.159
AST, aspartate alkaline phosphatase; APRI, AST to platelet ratio index; ECV, extracellular volume; ICG R15, retention rate of indocyanine green at 15 min; SV, spleen volume.
